Nama's AI scorecard currently rates Viatris Hold (4.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is VTRS's P/E ratio?

Viatris trades at a trailing price-to-earnings ratio of 7.8.

When does VTRS report earnings?

Viatris's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.61.

What is the VTRS price target?

The median analyst price target from 10 analysts is $20.00, with a range of $14.00 – $26.00.

Is VTRS Shariah compliant?

Nama's AAOIFI-style screen reads Viatris as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Does VTRS pay a dividend?

Yes — Viatris's dividend yield is 2.4%.

Nama Insights

Viatris (VTRS)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

S&P 500

Viatris (VTRS) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $22.87B, a trailing price-to-earnings ratio of 7.8 and a free-cash-flow yield of 7.9%. Over the most recent reported fiscal year, revenue declined 3.0% and free cash flow per share fell 3.0%. Nama's AI scorecard rates it Hold, 4.7 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Hold · 4.7/10

The sections balance. As of Nov 7, 2026.

Momentum

Leading · +73.0% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-0.2%

How far the last close sits under the highest price of the past five years.

Market cap	$22.87B
Trailing P/E	7.8
Price / book	1.6
Price / sales	1.6
FCF yield	7.9%
Dividend yield	2.4%
Gross margin	34.8%
Operating margin	0.9%
Net margin	-2.8%
Revenue growth (YoY)	-3.0%
Revenue growth (3-yr annual)	-4.2%
EPS growth (YoY)	-10.9%
FCF/share growth (YoY)	-3.0%
Beta	0.9
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

VTRS earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.61). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.71	$0.64	+10.9%	$3.75B
Q2 2026	Aug 6, 2026	$0.69	$0.60	+15.0%	$3.76B
Q1 2026	May 7, 2026	$0.59	$0.50	+18.0%	$3.52B
Q4 2025	Feb 26, 2026	$0.57	$0.53	+7.5%	$3.70B

VTRS analyst price target

Median target $20.00 from 10 analysts, ranging $14.00 – $26.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3
RDY	Dr. Reddy's Laboratories	$12.43B	20.4

Explore live VTRS data on Nama Insights →

VTRS FAQ

Is VTRS a buy?: Nama's AI scorecard currently rates Viatris Hold (4.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is VTRS's P/E ratio?: Viatris trades at a trailing price-to-earnings ratio of 7.8.
When does VTRS report earnings?: Viatris's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.61.
What is the VTRS price target?: The median analyst price target from 10 analysts is $20.00, with a range of $14.00 – $26.00.
Is VTRS Shariah compliant?: Nama's AAOIFI-style screen reads Viatris as Not Shariah Compliant. At least one of the three ratios or the industry test failed.
Does VTRS pay a dividend?: Yes — Viatris's dividend yield is 2.4%.